Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07285629 · ClinicalTrials.gov registry record · Early Phase 1

Safety and Efficacy of Klotho and Follistatin Gene Therapy

A Early Phase 1 study of Healthy Adults, sponsored by Minicircle.

Recruiting
Registry status
Early Phase 1
Development phase
30
Enrollment target
2
Study locations

NCT07285629 is a Early Phase 1 study of Healthy Adults that is actively recruiting participants, run by Minicircle. The registered enrollment target is 30 participants, below the 86-participant average among 33 other Healthy Adults trials with a reported enrollment target (65% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07285629, a Early Phase 1 study of Healthy Adults, is actively recruiting participants, sponsored by Minicircle.

RECRUITING
Registry status
Early Phase 1
Development phase
30 participants
Enrollment target
2
Study locations

Study Summary

The purpose of this study is to investigate the safety and efficacy of a combination klotho and follistatin gene therapy, delivered via a nonviral plasmid in healthy adult volunteers. Additionally, this study seeks to understand the cognitive and health benefits of this gene therapy.

Conditions Studied

Interventions

  • GENETIC Follistatin and klotho gene therapy

Study Locations (2)

Texas

  • Apeiron Center - Austin

Bay Islands

  • Global Alliance of Regenerative Medicine (GARM) Clinic - Roatán

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2025-12-16
Est. Completion 2026-06
Phase Early Phase 1

Sponsor

Minicircle

2 total trials

What the Registry Record Tells You About NCT07285629

The ClinicalTrials.gov registry entry for NCT07285629 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 86-participant average among 33 other Healthy Adults trials with a reported enrollment target (65% lower). The listed sponsor is Minicircle, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Healthy Adults appearing as the primary indexed condition, and to 1 intervention - of which Follistatin and klotho gene therapy is the first listed.

NCT07285629 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Texas, Bay Islands.

Frequently Asked Questions

What is clinical trial NCT07285629 about?

NCT07285629 is a clinical study titled "Safety and Efficacy of Klotho and Follistatin Gene Therapy". The purpose of this study is to investigate the safety and efficacy of a combination klotho and follistatin gene therapy, delivered via a nonviral plasmid in healthy adult volunteers. Additionally, this study seeks to understand the cognitive and health benefits of this gene therapy.

What is the current status of trial NCT07285629?

This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 30 participants. The study started on 2025-12-16. Estimated completion is 2026-06.

What conditions does trial NCT07285629 study?

This clinical trial studies the following conditions: Healthy Adults.

What interventions are being tested in trial NCT07285629?

The interventions under investigation include: Follistatin and klotho gene therapy (GENETIC).

Who is sponsoring clinical trial NCT07285629?

This trial is sponsored by Minicircle, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07285629 being conducted?

This trial has 2 study locations across Texas, Bay Islands. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy Adults

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.